Impaired wound healing and ulceration caused by diabetes mellitus,is a significant healthcare burden, markedly impairs quality of life for patients, and is the major cause of amputation worldwide. Current experimental approaches used to investigate the complex wound healing process often involve cultures of fibroblasts and/or keratinocytes in vitro, which can be limited in terms of complexity and capacity, or utilisation of rodent models in which the mechanisms of wound repair differ substantively from that in humans. However, advances in tissue engineering, and the discovery of strategies to reprogram adult somatic cells to pluripotency, has led to the possibility of developing models of human skin on a large scale. Generation of induced pluripotent stem cells (iPSC) from tissue donated by diabetic patients allows the (epi)genetic background of this disease to be studied, and the ability to differentiate iPSC to multiple cell types found within skin may facilitate the development of more complex skin models; these advances offer key opportunities for improving modelling of wound healing in diabetes, and the development of effective therapeutics for treatment of chronic wounds. (178 words) Perspectives  The cost of diabetic wounds to the National Health Service is estimated to be around £5 billion per year.
Introduction
Diabetes mellitus is a major global health concern, affecting around 425 million adults worldwide, a figure predicted to rise to 629 million people with diabetes by 2045 (International Diabetes Federation). Type 1 diabetes mellitus (T1DM) is an auto-immune disorder, caused by destruction of insulin-producing pancreatic -cells [reviewed in 1], while type 2diabetesmellitus (T2DM) is a polygenic condition characterised by loss of insulin secretion and sensitivity, strongly influenced by environmental factors such as obesity [2] .
Single gene disorders, such as neonatal diabetes, Maturity Onset Diabetes of the Young (MODY), and mitochondrial mutations (m.3243A>G), can trigger diabetes in younger age groups [3] . Diabetes mellitus also presents in a number of rare genetic conditions (congenital lipodystrophies [4] , Huntington's disease [5] , Friedreich ataxia [6] , and Turner syndrome [7] ), genetic obesity (Prader-Willi syndrome [8] , Alstrom syndrome [9] and premature aging conditions such as Werner [10] and Hutchinson-Gilford progeria [11] syndromes. It is a complex metabolic disorder, diagnosed clinically by hyperglycaemia [12] and associated with chronic inflammation, pro-coagulability, impaired fibrinolysis and macro-and microvascular defects, promoting cardiovascular disease (coronary heart disease and stroke) [13] , renal dysfunction [14, 15] , retinopathies [16] , neuropathies [16, 17] and impairment of wound healing in the extremities [17] [18] [19] [20] .Foot ulceration is major cause of morbidity in type 1 and type 2 diabetes, a significant healthcare burden, and results in markedly impaired quality of life for the patient. Globally, the prevalence of diabetic foot ulceration in 2017 was 6.3% (95% CI 5.4 to 7.3%) [20] anddiabetes is estimated to cause loss of a lower limb (or part thereof) to amputation every 30 seconds worldwide (International Diabetes Federation).
The healing of diabetic woundshas traditionally been investigated using animal models, immortalised cell lines and primary cells. Rodents are often used to examine the complex healing process in vivo, butdo not fully recapitulate the wound repair process in humans [21, 22] . Moreover, the requirement forreduction, refinement and replacement (3Rs) of animal models, and the severity of the procedures involved,mean that a valid replacement is ethically desirable. The use of human primary cells from dermal biopsiesto study wound repair in vitro, particularly in 3-dimensional (3-D) organotypic models,has provided valuable insights into the wound healing process: for example, the incorporation of diabetic patientderived fibroblasts into a 3-D model accurately replicated key features associated with chronic ulcersin vitro and in vivo [23] . This article will review these approaches, and highlight recent advances in reprogramming of adult somatic cells to pluripotency, which offer exciting opportunities to develop improved models for diabetic wound healing.
Wound healing: acute and chronic wounds
Wound healing involves four distinct, but overlapping phases: haemostasis, inflammation, proliferation and remodelling ( Table 1 ) [24] [25] [26] . Wound clotting is followed by reepithelisation at the wound edge around 12-18h post-wounding; concomitantly, a granulation tissue is formed by dermal fibroblasts at the wound margin, some of which convert to contractile myofibroblasts. Bone-marrow derived mesenchymal stem cells contribute to granulation tissuewhich contains a dense network of capillaries, and contraction reduces the surface area requiring re-epithelisation [22] [23] [24] [25] [26] . Neutrophils are recruited to the site of wounding, to kill microorganisms, followed by macrophages which phagocytose cell and matrix debris; these inflammatory cells then either die or leave the site of injury, aiding final resolution of the wound. 
Primary cells, immortalised cell lines and skin explants
The simplest cell-based model of wound healing in vitro involves culturing a monolayer ofprimary fibroblasts, keratinocytes or immortalised cells (e.g.HaCaT keratinocytes) and introducing a 'scrape' across the surface using a sterile pipette tip: the 'scratch' wound assay [31, 32, 33] . Migration of cells across the wound can be measured using static or time-lapse microscopy, and the expression of proteins involved in inflammation, migration, proliferation, differentiation and remodelling of the extracellular matrix investigated ( Table   1 ). Variability can be introduced into the system through changes in oxygen tension, the addition of drugs, growth factors or cytokines, or the use of extracellular matrices and specialised culture surfaces. These models can also be used to examine differences between healing and non-healing wounds, using normal and diabetic cells and altered tissue culture environments [23, [34] [35] [36] [37] [38] .
Since the 1970s there has been increasing interest in generating skin constructs which are physiologically relevant, capable of mimicking barrier formation, immune and sensory functions [39, 40] . Co-cultures of keratinocytes with other cell types, including immune cells and dermal fibroblasts, are often used for investigations of wound healing, but these cannot entirely replicate the cell-cell and cell-matrix interactions found in a 3-dimensional environment. The use of dermal fibroblasts encapsulated in gel/matrix, combined with differentiated keratinocytes forming a 3-D epidermis,often at the air-liquid interface, can address some of these limitations, and are useful for modelling changes in keratinocyte function, cytokine release after drug treatment, metabolism, irritation and sensitisation, and skin aging[23, 41-46]. Tissue-engineered skin products have also been used clinically (e.g. Apligraf, Dermagraft) to aid wound repair, particularly to provide barrier function [47, 48] .
However, the complexity of skin tissue, including the roles of a number of specialised cell types such as melanocytes, immune cells (macrophages, Langerhans cells, T cells, dendritic cells) and stem cell niches, and of skin appendages (hair follicles), sweat and sebaceous glands, obviously cannot be wholly recapitulated in cultures of just keratinocytes and/or fibroblasts.
Vascularisation can be achieved by the addition of endothelial cells, stimulated to form capillaries within the dermal environment, and to form a vascular network when supported by a suitable scaffold and perfusion system [49] . Other approaches have focused on the introduction of melanocytes, to study melanin transfer to keratinocytes, allowing studies of photoprotection and acquired (drug-induced) hyper-pigmentation [50], and the inclusion of hair follicles, sweat and sebaceous glands, to facilitate study of cosmetics, treatments for alopecia and sebo-regulating drugs [40] . The addition of immune cells, innervation of skin models, and introduction of the hypodermis (adipose tissue) are desirable for effective drug and allergen testing.
At present, however, it can be difficult to achieve some of these outcomes with primary cells derived from human skin biopsies, due to their limited availability and/or growth potential Despite the common use of animal models to study acute and chronic wound healing, physiological differences between species need to be considered [22, 59, 60] . Mouse and human skin have markedly different architecture, responsiveness and functionality, due to differences in thickness, hair density and appendages; murine skin is also largely devoid of sweat glands. Murine subcutaneous tissue has a thin layer of muscular tissue, the panniculus carnosus, which has substantive contractive potential; up to 90% of excisional wounds in mice close by contraction. By contrast, re-epithelization and formation of granulation tissue is the predominant mechanism of cutaneous wound healing in human dermis [22, 59, 60] . Attempts have been made to address this issue, by splinting excision wounds to more closely replicate wound healing in human skin; topical administration of platelet-derived growth factor (PDGF), for example, fails to promote closure of a splinted wound by re-epithelisation in db/db mice [61], despite its efficacy in othermurine models of wound healing. While wound splinting does allow histologic monitoring of wound bed granulation, the healing process still does not fully mimic human wound healing [22, 59, 60].
Outcomes from wound healing studies in rodents may therefore not be fully translatable to humans,possibly explaining the dearth of effective treatments currently available.
An alternativein vivo approach involves thegeneration of humanised mouse models.
Shunmugamet al (2015) grafted human skin biopsies from elective abdominoplasty surgery onto athymic (nu/nu) mice for three months, before inducing a excision wound into the graft, and monitoring wound healing using near infra-red fluorescent imaging [62] . Human skin constructs have also been transplanted onto immunodeficient mice: a 3-D matrix, enriched with fibrin from human blood plasma was seeded with human fibroblasts to form a dermis, before adding an epidermal layer using human keratinocytes [63] ; the same group have also described a humanised model of delayed wound healing in streptozotocin-induced diabetic mice [64] .It is clear, however, that all of these approaches to the study of wound healing in animals are classified as 'severe', likely to cause pain and distress: an ethical imperative exists to develop an in vitro translational model of human wound healing.
Induced pluripotent stem cells
The concept of cell plasticity originates from the groundbreaking work of John Gurdon in the 1960s [65] [66] [67] , culminating in the award of the Nobel Prize in Physiology or Medicine (2012) jointly with Shinya Yamanaka, more than forty years later; Yamanaka, together with Kazutoshi Takahashi, discovered how mature somatic cells can be reprogrammed to become pluripotent stem cells [68] [69] [70] . Induced pluripotent stem cells (iPSCs) can be derived from individuals with differing genetics, disease conditions or ethnic origins, and differentiated to cell types of the three germ layers, revolutionising research and drug discovery, and increasing the prospect of personalised regenerative medicine [68] [69] [70] [71] [72] [73] [74] . The direct reprogramming and trans-differentiation of somatic cells to specialised cell types, including those involved in diabetes and wound healing, has also been described; this approach bypasses the pluripotent stage and may therefore prove safer for cell therapy [86] [87] [88] .Primitive stem cells, such as hair follicle-associated-pluripotent (HAP) stem cells resident in the skin, also have potential to be converted to keratinocytes and melanocytes for therapeutic epidermal regeneration without the risk of tumour formation [89] . These approaches do not, however, offer the same opportunities for expansion and banking as conversion to pluripotency.
Pluripotent stem cells and generation of human skin constructs in vitro
The ability to model the complex interactions of whole tissues and organs using entirely human biology is a major goal for tissue engineering and stem cell research, and may eventually lead to the production of whole organs for transplantation [90] . Indeed, dermatology may be the ideal context for application of iPSC-based therapies, as it is readily accessible and easy to monitor, and excision is possible if adverse side effects occur [91] . Many of these challenges are also relevant to the development of accurate representations of tissue for disease modelling, including skin for wound healing assays. Regeneration of human epidermis in vivo using iPSCs is yet to be achieved, but the potential of this approach was recently demonstrated by Hirsch et al (2017) who utilised autologous transgenic keratinocyte cultures to renew the epidermis in a seven year old child suffering from severe JEB [96] . In this case, the epidermis was sustained by a limited number of long-lived stem cells or holoclones, self-renewal of which provided progenitor cells capable of replacing terminally differentiating keratinocytes [96] .
Notably, it seems that reprogrammed cells retain epigenetic features of the cell type of origin (although these disappear on continued passaging) and it has been suggested that this residual epigenetic memory may facilitate differentiation back to the corresponding original cell type [91, [97] [98] [99] . Intriguingly, the process of reprogramming down-regulates senescent pathways, elongates telomeres and restores mitochondrial function [100 -102] effectively 'rejuvenating' the cellular phenotype; indeed, 'rejuvenated' fibroblasts can also be generated from iPS cells derived from very old patients, offering new strategies for treatment of chronic wounds in the elderly [91, 102] .
Keratinocytes, fibroblasts and melanocytes have been successfully derived from human iPSCs, and iPSCs can be differentiated into immune cells (T-lymphocytes, macrophages and dendritic cells), endothelial and smooth muscle cells, Schwann cells and peripheral neurons [39, 40, 50, 103-107] and iPSC-derived ectodermal precursor cells can contribute to hair follicle morphogenesis in vivo [108] . Thus, iPSC-derived skin cells have huge potential for skin tissue engineering, and for the development of in vitro skin models for healthy and diseased skin, and inacute and chronic wound healing studies.
Human skin equivalents (HSE) have been generated using iPSC-derived fibroblasts and/orkeratinocytes [106] [107] [108] [109] . The transcriptome of iPSC-derived keratinocytes proved very similar to primary healthy human keratinocytes, while incubation of iPSC-derived keratinocytes at an air/liquid interface resulted in epidermal stratification and the development of a functional permeability barrier [109] . Itoh et al (2011) generated an in vitro 3-D skin equivalent, using a type I collagen matrix to support iPSC-derived fibroblasts in the dermis, and iPSC-derived keratinocytes to form an epidermis, and demonstrated normal morphology, stratification and terminal differentiation at the air-liquid interface [107] . approaches [112] . Other limitations include variability among iPSC cell lines [113] and genomic instability [114, 115] . The establishment of selection criteria for iPSC and iPSCderived cells, such as cell-specific markers, assessment of proliferation rate and lifespan, and investigation of the transcriptome [112, 113] ,can help to minimise variability, while limiting replication stress during reprogramming, either genetically by targeting checkpoint kinase 1 (CHK1) or by using nucleoside supplementation, can help to reduce genomic instability [115] . The quality of 3-D skin constructs should also meet key criteria such as histological morphology, cell viability and barrier function [106] [107] [108] [109] .
Pluripotent stem cells derived from diabetic individuals: disease modelling
Induced pluripotent stem cells have been derived from individuals with monogenic forms of diabetes, and from patients with type 1 and type 2 diabetes mellitus, facilitating research into multiple aspects of the complex pathogenesis of these disorders ( Table 2) , although it is clear that the potential for utilisation of these cells in studies of diabetic wound healing is yet to be fully realised.The autoimmunity that arises in T1DM results from a complex interaction between genetic and immunologic factors [1] . Risk of T1DM progression is polygenic, with a large number of genes conferring small risk effects, and a small number of genes having large effects, most particularly the human leukocyte antigens (HLA) DR/DQ alleles (e.g. DRB1*03-DQB1*0201 (DR3) or DRB1*04-DQB1*0302 (DR4) [1] . To date, genomic wide association studies have identified at least 75 independent genetic loci for T2DM although whether all of these variants are causal is not known, and their mechanism of action requires further clarification [2, 136, 137] . Further, most of the common variants This may pose a significant problem in cell replacement therapy designed to correct defects in diabetic patients; for example, the generation of functional insulin-secreting pancreatic cells from iPSCs, for potential cell replacement therapy represents a key goal for treatment of type 1 and type 2 diabetes [139] .Induced pluripotent stem cells have been generated from fibroblasts from ulcerated skin of diabetic foot ulcer patients, and compared with those from non-ulcerated diabetic skin and from healthy individuals: all of the skin fibroblasts were reprogrammed to iPSC with similar efficiencies, indicating that even repair-deficient fibroblasts may be useful therapeuticsfor wound healing [134] . Human iPS cells from Type 1 diabetic patients have also been differentiated into early vascular cells and mature endothelial cells which can assemble into 3-D networks when embedded in engineered matrices, incorporate into developing zebrafish vasculature, and may prove to be a useful in vascular repair for diabetic patients [133] . The challenges currently facing this type of regenerative cell therapy, which are outwith the scope of this review, have been recently and comprehensively reviewed [73, [112] [113] [114] [115] 140] .
Arguably, however, retention of the diabetic epigenome, together with the presence of genetic variations which increase the risk of T2D, may facilitate the development of authentic models, including wound healing, of this disease in vitro. To date, dermal fibroblasts, from patients with the mitochondrial A3243G mutation, associated with maternal inherited diabetes and deafness (MIDD) have been used to generate heteroplasmic iPSC clones for studies of mitochondrial function [117] . Isogenic iPS clones with either high levels of this mutation or undetectable levels of the mutation, from the same individuals;
complex I activity, mitochondrial respiration and ATP production were compromised in some of the mutation-high clones, while those from the mutation-undetectable clones were similar to those of iPS cells from healthy subjects [117] . Defects in insulin production and gene correction.
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